Related Experiment Video

Updated: Aug 10, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib

Francis Yew Fu Tieng1,2,3, Sri Kisha Subramaniam1,2, Po Lin Ooi1,2

  • 1Department of Clinical Oncology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.

Gynecologic Oncology Reports
|August 8, 2026
PubMed
Summary

Advanced uterine leiomyosarcoma (uLMS) can be treated with targeted ALK inhibitors like ceritinib. Molecular profiling identified an ALK fusion, leading to durable remission in a challenging case.

Keywords:
ALK fusionCeritinibImmunotherapy toxicityTargeted therapyUterine leiomyosarcomaUterine sarcoma

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...